Last Price$20.72.1%
Market Cap$972.8M
N/A
Industry median - 13.4%
5Y Historical average - N/A
56.7%
Industry median - 0.3%
5Y Historical average - 83.9%
N/A
Industry median - (20.6%)
5Y Historical average - 118.7%
34.6%
Industry median - (1.7%)
5Y Historical average - 109.5%
ELVN Growth Rating
ELVN Growth rating
6.9
ELVN Growth rating performance
ELVN Growth Metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with ELVN Growth
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Growth score | Revenue Growth
(5Y CAGR) | Revenue Growth
(YoY) | Revenue Growth
(FWD) | EPS Growth
(5Y CAGR) | EPS Growth
(YoY) | EPS Growth
(FWD) | FCF Growth
(5Y CAGR) | FCF Growth
(YoY) |
$972.8M | 6.9 | N/A | N/A | N/A | (12.7%) | N/A | (3.2%) | 37.4% | 34.6% | |
$124.8B | 6.9 | 21.5% | 11.5% | 8.6% | N/A | N/A | (962.4%) | N/A | N/A | |
$77.0B | 5.6 | 12.6% | 8.3% | 2.4% | 16.1% | 10.3% | 3.1% | 12.5% | (5.7%) | |
$34.4B | 6.3 | 106.9% | 127.3% | 76.3% | (9.7%) | (57.5%) | (132.2%) | N/A | (70.8%) | |
$30.7B | 5.4 | 59.2% | 23.0% | 28.6% | (23.2%) | (38.5%) | (26.5%) | (36.7%) | N/A | |
$24.0B | 6.2 | 90.9% | (28.0%) | (28.0%) | 36.5% | N/A | (182.9%) | (3.1%) | N/A | |
$14.5B | 4.0 | 4.5% | (3.8%) | 35.4% | (19.0%) | (9.0%) | 144.6% | 10.7% | (7.3%) | |
$13.8B | 7.5 | 14.7% | 23.6% | 9.1% | N/A | 25.6% | 6.8% | N/A | 44.5% | |
$13.4B | 7.1 | 10.8% | 17.8% | 10.0% | N/A | 152.8% | 48.9% | N/A | 820.5% | |
$13.3B | 6.1 | (100.0%) | N/A | N/A | (0.9%) | (92.8%) | 11.4% | 44.6% | 84.8% | |
$1,846.9M | 5.9 | 50.5% | 50.5% | 50.7% | 25.3% | 20.9% | (35.6%) | 3.3% | (43.8%) |
FAQ
What is the Enliven Therapeutics, Inc. (ELVN) revenue growth?
The Enliven Therapeutics, Inc. (ELVN) revenue growth is N/A, which is lower than the industry median of 13.4% and the 5-year historical average of N/A.
What is the Enliven Therapeutics, Inc. (ELVN) operating income growth?
The Enliven Therapeutics, Inc. (ELVN) operating income growth is 56.7%, compared to the industry median of 0.3% and the 5-year historical average of 83.9%.
What is the Enliven Therapeutics, Inc. (ELVN) EPS (Earnings Per Share) growth?
The Enliven Therapeutics, Inc. (ELVN) EPS growth is N/A, compared to the industry median of (20.6%) and the 5-year historical average of 118.7%.
What is the Enliven Therapeutics, Inc. (ELVN) Free Cash Flow (FCF) growth?
The Enliven Therapeutics, Inc. (ELVN) Free Cash Flow growth is 34.6%, compared to the industry median of (1.7%) and the 5-year historical average of 109.5%.